This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Diabetes Obesity Outcomes 
Science Daily - Heart Disease
NOVEMBER 25, 2024
The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without diabetes.
118 
Cardiometabolic Health Congress
FEBRUARY 10, 2025
Obesity is a complex, chronic condition that significantly impacts cardiometabolic health and overall well-being. 1 Dietary Modifications: Evidence-Based Approaches Low-Fat vs. Low-Carb Diets A meta-analysis of 48 randomized controlled trials (RCTs) revealed no significant difference in weight loss outcomes between low-fat and low-carb diets.
52 
CardiacWire
JANUARY 22, 2025
Starting with the good news, GLP-1s lowered risks for 42 health outcomes while increasing risks for 19 outcomes. Its also worth noting that the data came from military veterans who were older and mainly white, so the outcomes might not apply to other populations. year follow-up.
59 
American College of Cardiology
APRIL 10, 2024
What are the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction (HFpEF) with and without diabetes, and consistency across key patient subgroups?
NEJM Journal Watch - Cardiology
APRIL 7, 2024
In a randomized, controlled trial, semaglutide resulted in greater weight loss, improved symptoms, and fewer serious adverse events compared with placebo.
74 
HeartRhythm
APRIL 30, 2024
We have previously shown an association between metabolic syndrome (MS) and heart failure (HF) outcomes in patients with implanted defibrillators (ICD) and cardiac resynchronization therapy (CRT-D). However, the role of MS and diabetes in predicting HF outcomes was not assessed in non-obese patients.
American College of Cardiology
DECEMBER 14, 2023
The goal of the SELECT trial was to determine the association of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), with cardiovascular (CV) events in a secondary prevention cohort of patients with overweight or obesity and prior CV disease (CVD) without diabetes mellitus (DM).
56 The New England Journal of Medicine
NOVEMBER 10, 2023
In a trial in patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8
40 
Open Heart
MAY 23, 2024
Background and aims Pre-eclampsia complicates 3–5% of pregnancies worldwide and is associated with adverse outcomes for the mother and the offspring. Pre-eclampsia and heart failure have common risk factors, including hypertension, obesity and diabetes.
DAIC
JUNE 18, 2024
A projected rise in heart disease and stroke – along with several key risk factors, including high blood pressure and obesity – is likely to triple related costs to $1.8 A projected rise in heart disease and stroke – along with several key risk factors, including high blood pressure and obesity – is likely to triple related costs to $1.8
105 
Cardiovascular Diabetology
FEBRUARY 16, 2025
Obesity is common in the heart failure (HF) population and is regarded as an important risk factor for developing HF. Greater skeletal muscle mass has shown to be the underlying protective factor against cardi.
Journal of the American Heart Association
DECEMBER 29, 2023
Obesity significantly increases AF risk, both directly and indirectly, through related conditions, like hypertension, diabetes, and heart failure. In particular, expanding epicardial adipose tissue during obesity has been suggested as a key driver of AF via paracrine signaling and direct infiltration.
45 
CardiacWire
FEBRUARY 11, 2024
The associations between obesity and hypertension are widely known, but a new JACC study reveals that weight-reducing gastric bypass surgery has a significant and lasting impact on patients’ need for antihypertensives. The GATEWAY trial assigned 100 participants (76% women, 43.8 of them achieved BPs below 130/80 mm Hg (vs.
111 
Cardiometabolic Health Congress
JUNE 27, 2024
Neha Agarwal, PhD, Clinical Director at Cardiometabolic Health Congress , Informa Connect, recently presented significant findings at the 84th American Diabetes Association (ADA) Scientific Sessions. Competence in selecting treatments for long-term obesity management rose from 43% pre-test to 95% post-test.
59 
American College of Cardiology
JANUARY 23, 2024
The SELECT trial extends findings from previous trials, which demonstrated cardiovascular benefit in diabetes mellitus (DM), to those without DM.
45 Science Daily - Heart Disease
OCTOBER 10, 2023
Pregnancy complications such as preeclampsia and gestational diabetes have recently been associated with a higher risk of developing heart disease later in life. But a new study has found obesity before or during pregnancy is the actual root cause of future cardiovascular disease. “We
40 
Cardiometabolic Health Congress
JULY 25, 2024
Practical, Future-Focused Education Cardiorenal and metabolic diseases, fueled by poor lifestyle choices and health conditions, lead to type 2 diabetes, cardiovascular disease, and chronic kidney disease. The robust conference agenda begins with FDA updates and advancements in cardiorenal metabolic care.
100 
Cardiometabolic Health Congress
JUNE 24, 2024
As a leader in the field of research-based cardiometabolic health education, CMHC is proud to present its CME education outcomes study at ADA (American Diabetes Association) 2024 Scientific Sessions, which offers its education-focused agenda to a wide number of healthcare practitioners from all areas of the U.S.
52 European Journal of Heart Failure
DECEMBER 7, 2023
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Echocardiography demonstrated increased CO with obesity, but not estimated right atrial (RA) pressure or E/e′. Overall, 60.9%
CardiacWire
MARCH 24, 2024
Less than two weeks after Novo Nordisk’s weight-loss drug Wegovy gained expanded FDA approval for cardiovascular event risk reduction, CMS issued a new Medicare Part D guidance that allows coverage of obesity drugs for senior patients with “an additional medically accepted indication”… like cardiovascular disease.
59 
Cardiometabolic Health Congress
OCTOBER 18, 2024
Somers, MD, PhD , a consultant in cardiovascular medicine from the Mayo Clinic, discusses how sleep impacts both cardiovascular and metabolic outcomes. There is a clear relationship between sleep deprivation and the development of conditions like obesity, diabetes, and hypertension. In this week’s CMHC Pulse Blog Post, Virend K.
CardiacWire
MARCH 13, 2024
Wegovy’s expanded FDA approval now supports its use for the reduction of major adverse cardiovascular events in obese or overweight adults with established CVD. Semeglutide was already approved for diabetes (via Ozempic) and weight loss (via Wegovy), although payors have largely resisted covering non-diabetic patients.
64 
Journal of the American Heart Association
FEBRUARY 14, 2024
One such syndrome that has been associated with poor outcomes is cognitive frailty: the simultaneous presence of cognitive impairment, without evidence of dementia, and physical frailty, which results in decreased cognitive reserve.
Stroke Journal
FEBRUARY 1, 2024
Introduction:The paucity of large-scale data exploring the effect of prior bariatric surgery on recurrent stroke outcomes in elderly obese stroke survivors led us to address the gap, with an emphasis on the risk of recurrent stroke and its trends.Methods:A retrospective study was conducted using National Inpatient Sample data from 2016-2019.
40 
Dr. Paddy Barrett
AUGUST 30, 2024
Insulin resistance is a precursor condition to metabolic syndrome and type 2 diabetes, both major drivers of heart disease. Obesity is one of the biggest global health concerns we face today. Obesity is also a key driver of risk for cardiovascular disease. Obesity (Silver Spring). hour sleep-per-night group.
111 
DAIC
FEBRUARY 29, 2024
This year’s theme, “Advancing Cardiovascular Care for All” brings the latest practice-changing breakthroughs, along with top experts debating and discussing outcomes of highly-anticipated clinical trials. 24 from April 6 - 8, 2024 in Atlanta, GA at the Georgia World Congress Center.
103 
Stroke Journal
FEBRUARY 1, 2024
Malnutrition is common in stroke patients and leads to worse outcomes. Body mass index (BMI) is a widely available marker of nutrition status, however studies on BMI and post-ICH outcomes are limited and have conflicting results. There was no association between BMI and ICH volume in patients with deep or lobar hemorrhage.
40 
Cardiometabolic Health Congress
JUNE 7, 2024
Untangling the Statins and Diabetes Link : Dr. Savitha Subtamaniam explored the incidence of diabetes associated with statin use, noting that the mechanism is unclear. She also highlighted uncertainty regarding whether statins worsen glycemic management in individuals with pre-existing diabetes.
Science Daily - Heart Disease
NOVEMBER 13, 2023
Semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who do not have diabetes, according to new research. In the trial, patients treated with semaglutide lost an average of 9.4%
40 
Stroke Journal
FEBRUARY 1, 2024
Diabetes mellitus not only heightens the risk of IS but also aggravates its outcomes. db/db mice were used to model type 2 diabetes and obesity, while db/+ mice served as euglycemic controls. Stroke, Volume 55, Issue Suppl_1 , Page A21-A21, February 1, 2024.
40 
Frontiers in Cardiovascular Medicine
APRIL 30, 2024
Peripheral artery disease (PAD) continues to increase in prevalence worldwide due to risk factors such as advanced age, diabetes mellitus, and obesity. This paper presents a brief overview of the structure of the multidisciplinary team with key components and functions of such a team to optimize treatment outcomes for PAD and CLTI.
Cardiometabolic Health Congress
AUGUST 14, 2024
The focus will be on the intricate interplay between cardiorenal and metabolic conditions, such as type 2 diabetes, cardiovascular disease, and chronic kidney disease, driven by lifestyle and health factors. Attendees will gain valuable clinical insights and explore cutting-edge therapies aimed at improving overall health outcomes. “Dr.
72 
International Journal of Cardiovascular Sciences
MARCH 13, 2023
These factors include obesity, dyslipidemia, hypertension, and insulin resistance — also known as metabolic syndrome. Numerous pharmacological and non-pharmacological interventions have been developed to control and improve clinical outcomes, and all these aspects involve cardiometabolic diseases.
52 
ADN Center of Excellence
SEPTEMBER 2, 2024
Factors such as aging populations, rising rates of obesity, hypertension, and other cardiovascular conditions contribute to this increase. Regular screening, especially in high-risk populations, can lead to earlier intervention and better outcomes. By 2050, the number of individuals affected by AFib is expected to more than double.
59 Journal of the American Heart Association
FEBRUARY 26, 2025
BackgroundMultimorbidity is common among patients with atrial fibrillation (AF) and is associated with worse outcomes. Multimorbidity was defined as 2 comorbidities (heart failure, hypertension, diabetes, coronary heart disease, kidney dysfunction, moderate or severe mitral valve regurgitation, or obesity).
Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
IntroductionThe Appalachia region of North America is known to have significant health disparities, specifically, worse risk factors and outcomes for stroke. These subjects underwent MT for ELVO, and during the procedure, carotid arterial blood samples were acquired and subsequently sent for proteomic analysis.
ADN Center of Excellence
SEPTEMBER 2, 2024
Factors such as aging populations, rising rates of obesity, hypertension, and other cardiovascular conditions contribute to this increase. Regular screening, especially in high-risk populations, can lead to earlier intervention and better outcomes. By 2050, the number of individuals affected by AFib is expected to more than double.
52 
Circulation
NOVEMBER 11, 2024
Age-standardized prevalence rates were calculated for eight conditions, including hypertension, type 2 diabetes, alcohol use, smoking, physical inactivity, overweight/obesity, short sleep (< 7 hours), and CVD (defined as having coronary heart disease, heart attack, or stroke). p< 0.001) and alcohol use (AAPC: 2.3%,p<
40 
Dr. Paddy Barrett
AUGUST 16, 2024
Overweight/Obesity. Falling into the class of obesity with a BMI of greater than 30 makes this more likely, but so also does having excess visceral fat deposition with significant metabolic consequences at a BMI less than 30. Weight Loss Potential With Obesity Medications. ” here is what I tell them.
52 
Physiologically Speaking
DECEMBER 27, 2023
The throng of epidemiological evidence hasn’t helped either — one week “butter is back” and the next, red meat is giving us diabetes. While individuals adhering to plant-based diets may exhibit better health outcomes than their meat-eating counterparts, attributing this solely to dietary choices is jumping the gun.
69 
Cardiometabolic Health Congress
NOVEMBER 8, 2023
2023, the American Heart Association (AHA) issued a presidential advisory on the urgency of this systemic disorder involving heart disease, kidney disease, diabetes and obesity. The virtual, self-paced Foundations of Cardiometabolic Health Certificate Course is the first step to attaining the CCHP credential.
Cardiometabolic Health Congress
SEPTEMBER 29, 2023
Cardiometabolic conditions – specifically obesity, diabetes and heart disease – disproportionately affect the 60 million people in the U.S. Dr. Rodriguez presents to hundreds of practitioners of women's health on using digital tools and community intervention to improve outcomes in underserved ethnic populations. Register Now
Stroke Journal
DECEMBER 19, 2024
The latest research on socioeconomic status (SES) and stroke continues to demonstrate that individuals with low SES are at a higher risk of stroke, receive lower-quality care, and experience poorer outcomes.
40 
Stroke Journal
JANUARY 30, 2025
National Inpatient Sample (NIS) database from 2009 to 2020, evaluating patients who presented with stroke from ICAD and were treated with angioplasty and stenting and analyzed presenting co-morbidities and patient outcomes. vs 7.9%), diabetes (33.6% vs 4.6%), obesity (26.4%
40
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content